In the SARS-CoV-2 era, do we need to be afraid of obinutuzumab?

Joleen Choy, Katharine L. Lewis

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'In the SARS-CoV-2 era, do we need to be afraid of obinutuzumab?'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry